Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.

What is known and objectives: Tacrolimus, an immunosuppressant, has been used to treat paediatric systemic lupus erythematosus, but the optimal initial regimen is not clear. The purpose of this study was to explore the optimal initial dose of tacrolimus for children with systemic lupus erythematosus...

Full description

Bibliographic Details
Published in:Journal of Clinical Pharmacy & Therapeutics Vol. 45; no. 2; pp. 309 - 318
Main Authors: Chen, Xiao, Wang, Dongdong, Xu, Hong, Li, Zhiping
Format: equations & formulas research tables/charts Journal Article
Published: Wiley-Blackwell Apr2020
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142038952&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 142038952
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Apr2020
      vid: 45
      iid: 2
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        142038952
        142038952
        145835419
        142038952
        10.1111/jcpt.13072
        142038952
      ppf: 309
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
      aug:
        au:
          Chen, Xiao
          Wang, Dongdong
          Xu, Hong
          Li, Zhiping
        affil: Department of Pharmacy, Children's Hospital of Fudan University, Shanghai, China
      sug:
        subj:
          Tacrolimus Administration and Dosage
          Tacrolimus Therapeutic Use
          Tacrolimus Pharmacokinetics
          Fruit Administration and Dosage
          Capsules
          Lupus Erythematosus, Systemic Drug Therapy
          Cytochrome P-450 Enzyme System
          Polymorphism, Genetic
          Pharmacogenetics
          Lupus Erythematosus, Systemic Familial and Genetic
          Pediatric Care
          Human
          Linear Regression
          Genotype
          Alleles
          Child
          Adolescence
          Child: 6-12 years
          Adolescent: 13-18 years
      ab: What is known and objectives: Tacrolimus, an immunosuppressant, has been used to treat paediatric systemic lupus erythematosus, but the optimal initial regimen is not clear. The purpose of this study was to explore the optimal initial dose of tacrolimus for children with systemic lupus erythematosus using population pharmacokinetics and pharmacogenomics. Methods: Clinical information, tacrolimus concentrations and related genetic polymorphisms were incorporated into a model using non‐linear mixed‐effects modelling (NONMEM) analysis. Results and discussion: The results showed that weight, the CYP3A5 genotype and combined treatment with Wuzhi capsule can affect tacrolimus clearance in children with systemic lupus erythematosus. Furthermore, at the same weight, the ratios of tacrolimus clearance were 1:2.49:0.57:1.4193 from people who were CYP3A5*3/*3 and did not take Wuzhi capsule, people who had the CYP3A5*1 allele and did not take Wuzhi capsule, people who were CYP3A5*3/*3 and took Wuzhi capsule, and people who had the CYP3A5*1 allele and took Wuzhi capsule, respectively. In addition, we found that 0.10 mg/kg split into two doses was suitable for people with weights from 10 to 60 kg who were CYP3A5*3/*3 and did not take Wuzhi capsule, who were CYP3A5*3/*3 and took Wuzhi capsule, and who had the CYP3A5*1 allele and took Wuzhi capsule. In people who had the CYP3A5*1 allele and did not take Wuzhi capsule, 0.15 mg/kg split into two doses was appropriate for those with weights from 10 to 40 kg and 0.10 mg/kg split into two doses was appropriate for those with weights from 40 to 60 kg. What is new and conclusion: This study is the first study to recommend an optimal initial regimen of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration of Wuzhi capsule.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N